E
Akari Therapeutics, Plc
AKTX
$1.10
-$0.095-7.98%
E
Sell
11/12/2024Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 11/12/2024 due to a decline in the volatility index, total return index and growth index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 11/12/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
10/28/2024Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 10/28/2024 due to a substantial increase in the valuation index and volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 10/28/2024 due to a substantial increase in the valuation index and volatility index.
E
Sell
9/26/2024Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 9/26/2024 due to a decline in the volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 9/26/2024 due to a decline in the volatility index.
D
Sell
9/11/2024Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 9/11/2024 due to an increase in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 9/11/2024 due to an increase in the total return index and volatility index.
E
Sell
8/27/2024Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 8/27/2024 due to a decline in the growth index and efficiency index. Net income declined 35.79% from -$5.57M to -$7.56M, and operating cash flow declined 21.02% from -$4.04M to -$4.89M.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 8/27/2024 due to a decline in the growth index and efficiency index. Net income declined 35.79% from -$5.57M to -$7.56M, and operating cash flow declined 21.02% from -$4.04M to -$4.89M.
D
Sell
7/1/2024Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 7/1/2024 due to an increase in the growth index, efficiency index and total return index.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 7/1/2024 due to an increase in the growth index, efficiency index and total return index.
E
Sell
3/14/2023Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 02/23/2023.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/16/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 11/16/2022 due to a decline in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 11/16/2022 due to a decline in the total return index and volatility index.
D
Sell
11/1/2022Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 11/1/2022 due to an increase in the volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 11/1/2022 due to an increase in the volatility index.
D
Sell
10/17/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 10/17/2022 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 69.79% from -$5.05M to -$8.57M, the quick ratio declined from 3.03 to 2.68, and EBIT declined 10.91% from -$5.24M to -$5.82M.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 10/17/2022 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 69.79% from -$5.05M to -$8.57M, the quick ratio declined from 3.03 to 2.68, and EBIT declined 10.91% from -$5.24M to -$5.82M.
D
Sell
7/21/2022Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 7/21/2022 due to a substantial increase in the growth index and solvency index. The quick ratio increased from 1.54 to 3.03, earnings per share increased from -$12.15 to -$9.66, and EBIT increased 10.7% from -$5.87M to -$5.24M.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 7/21/2022 due to a substantial increase in the growth index and solvency index. The quick ratio increased from 1.54 to 3.03, earnings per share increased from -$12.15 to -$9.66, and EBIT increased 10.7% from -$5.87M to -$5.24M.
D
Sell
7/1/2022Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 7/1/2022 due to an increase in the volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 7/1/2022 due to an increase in the volatility index.
E
Sell
6/15/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 6/15/2022 due to a decline in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 6/15/2022 due to a decline in the total return index and volatility index.
D
Sell
5/23/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 5/23/2022 due to a substantial decline in the growth index, solvency index and total return index. EBIT declined 301.26% from -$1.46M to -$5.87M, earnings per share declined from -$3.12 to -$12.15, and operating cash flow declined 221.01% from -$1.56M to -$5M.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 5/23/2022 due to a substantial decline in the growth index, solvency index and total return index. EBIT declined 301.26% from -$1.46M to -$5.87M, earnings per share declined from -$3.12 to -$12.15, and operating cash flow declined 221.01% from -$1.56M to -$5M.
D
Sell
5/16/2022Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from E+ on 05/16/2022.
Akari Therapeutics, Plc (AKTX) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and total return index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.71 to 1.17.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.71 to 1.17.
D
Sell
7/16/2021Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D from D+ on 7/16/2021 due to a noticeable decline in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to D from D+ on 7/16/2021 due to a noticeable decline in the total return index and volatility index.
D
Sell
7/1/2021Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D+ from D on 7/1/2021 due to a substantial increase in the growth index. Earnings per share increased from -$25.96 to -$15.18, and EBIT increased 19.53% from -$6.9M to -$5.55M.
Akari Therapeutics, Plc (AKTX) was upgraded to D+ from D on 7/1/2021 due to a substantial increase in the growth index. Earnings per share increased from -$25.96 to -$15.18, and EBIT increased 19.53% from -$6.9M to -$5.55M.
D
Sell
4/26/2021Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D from D+ on 4/26/2021 due to a substantial decline in the growth index. EBIT declined 2,692.83% from -$246.9 to -$6.9M, earnings per share declined from $4.26 to -$25.96, and operating cash flow declined 501.12% from -$704.2 to -$4.23M.
Akari Therapeutics, Plc (AKTX) was downgraded to D from D+ on 4/26/2021 due to a substantial decline in the growth index. EBIT declined 2,692.83% from -$246.9 to -$6.9M, earnings per share declined from $4.26 to -$25.96, and operating cash flow declined 501.12% from -$704.2 to -$4.23M.
D
Sell
1/20/2021Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D+ from D on 1/20/2021 due to a large increase in the total return index and volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D+ from D on 1/20/2021 due to a large increase in the total return index and volatility index.
D
Sell
12/11/2020Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 12/11/2020 due to a major increase in the growth index and solvency index. Earnings per share increased from -$27.7 to $4.26, EBIT increased 95.07% from -$5.01M to -$246.9, and operating cash flow increased 83.52% from -$4.27M to -$704.2.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 12/11/2020 due to a major increase in the growth index and solvency index. Earnings per share increased from -$27.7 to $4.26, EBIT increased 95.07% from -$5.01M to -$246.9, and operating cash flow increased 83.52% from -$4.27M to -$704.2.
D
Sell
9/18/2020Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 9/18/2020 due to a major decline in the growth index. Earnings per share declined from -$13.45 to -$27.7, and EBIT declined 1.72% from -$4.93M to -$5.01M.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 9/18/2020 due to a major decline in the growth index. Earnings per share declined from -$13.45 to -$27.7, and EBIT declined 1.72% from -$4.93M to -$5.01M.
D
Sell
5/29/2020Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 5/29/2020 due to a large increase in the growth index and solvency index. Earnings per share increased from -$42.1 to -$13.45, the quick ratio increased from 0.67 to 0.96, and EBIT increased 37.05% from -$7.83M to -$4.93M.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 5/29/2020 due to a large increase in the growth index and solvency index. Earnings per share increased from -$42.1 to -$13.45, the quick ratio increased from 0.67 to 0.96, and EBIT increased 37.05% from -$7.83M to -$4.93M.
D
Sell
5/20/2020Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 5/20/2020 due to a large decline in the growth index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 5/20/2020 due to a large decline in the growth index and volatility index.
D
Sell
5/1/2020Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index, solvency index and volatility index.
Akari Therapeutics, Plc (AKTX) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index, solvency index and volatility index.
D
Sell
4/1/2020Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D+ from D on 4/1/2020 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 29.45% from -$4.91M to -$3.46M.
Akari Therapeutics, Plc (AKTX) was upgraded to D+ from D on 4/1/2020 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 29.45% from -$4.91M to -$3.46M.
D
Sell
8/30/2019Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 8/30/2019 due to a major increase in the efficiency index.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 8/30/2019 due to a major increase in the efficiency index.
D
Sell
6/5/2019Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 6/5/2019 due to a decline in the efficiency index, solvency index and volatility index. Total capital declined 60.78% from $3.11M to $1.22M, and the quick ratio declined from 1.11 to 0.81.
Akari Therapeutics, Plc (AKTX) was downgraded to D- from D on 6/5/2019 due to a decline in the efficiency index, solvency index and volatility index. Total capital declined 60.78% from $3.11M to $1.22M, and the quick ratio declined from 1.11 to 0.81.
D
Sell
3/13/2019Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 3/13/2019 due to an increase in the volatility index and total return index.
Akari Therapeutics, Plc (AKTX) was upgraded to D from D- on 3/13/2019 due to an increase in the volatility index and total return index.
D
Sell
11/20/2018Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 11/20/2018 due to a major increase in the growth index, efficiency index and solvency index. Earnings per share increased from -$100 to -$23.51, net income increased 55.21% from -$8.02M to -$3.59M, and operating cash flow increased 35.64% from -$8.28M to -$5.33M.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 11/20/2018 due to a major increase in the growth index, efficiency index and solvency index. Earnings per share increased from -$100 to -$23.51, net income increased 55.21% from -$8.02M to -$3.59M, and operating cash flow increased 35.64% from -$8.28M to -$5.33M.
E
Sell
9/28/2018Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 9/28/2018 due to a decline in the growth index and solvency index. Earnings per share declined from -$8.77 to -$100, operating cash flow declined 88.36% from -$4.4M to -$8.28M, and EBIT declined 85.32% from -$4.31M to -$7.98M.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 9/28/2018 due to a decline in the growth index and solvency index. Earnings per share declined from -$8.77 to -$100, operating cash flow declined 88.36% from -$4.4M to -$8.28M, and EBIT declined 85.32% from -$4.31M to -$7.98M.
D
Sell
7/20/2018Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 7/20/2018 due to an increase in the growth index, solvency index and total return index. Operating cash flow increased 7.56% from -$9.21M to -$8.52M, the quick ratio increased from 2.25 to 2.37, and earnings per share increased from -$100 to -$95.37.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 7/20/2018 due to an increase in the growth index, solvency index and total return index. Operating cash flow increased 7.56% from -$9.21M to -$8.52M, the quick ratio increased from 2.25 to 2.37, and earnings per share increased from -$100 to -$95.37.
E
Sell
4/24/2018Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 4/24/2018 due to a decline in the volatility index and total return index.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 4/24/2018 due to a decline in the volatility index and total return index.
D
Sell
4/9/2018Upgraded
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 4/9/2018 due to an increase in the volatility index.
Akari Therapeutics, Plc (AKTX) was upgraded to D- from E+ on 4/9/2018 due to an increase in the volatility index.
E
Sell
3/12/2018Downgrade
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 3/12/2018 due to a significant decline in the volatility index, total return index and growth index. Earnings per share declined from -$2.72 to -$100, operating cash flow declined 96.1% from -$4.7M to -$9.21M, and EBIT declined 16.22% from -$7.35M to -$8.54M.
Akari Therapeutics, Plc (AKTX) was downgraded to E+ from D- on 3/12/2018 due to a significant decline in the volatility index, total return index and growth index. Earnings per share declined from -$2.72 to -$100, operating cash flow declined 96.1% from -$4.7M to -$9.21M, and EBIT declined 16.22% from -$7.35M to -$8.54M.
D
Sell
9/17/2015Downgrade
Celsus Therapeutics Plc (CLTX) was downgraded to D- from D on 9/17/2015 due to a decline in the efficiency index, valuation index and solvency index. Total capital declined 62.5% from $2.6M to $973, the quick ratio declined from 4.54 to 2.89, and net income declined 27.88% from -$2.32M to -$1.67M.
Celsus Therapeutics Plc (CLTX) was downgraded to D- from D on 9/17/2015 due to a decline in the efficiency index, valuation index and solvency index. Total capital declined 62.5% from $2.6M to $973, the quick ratio declined from 4.54 to 2.89, and net income declined 27.88% from -$2.32M to -$1.67M.
D
Sell
6/2/2014Upgraded
Celsus Therapeutics Plc (CLTX) was upgraded to D from D- on 6/2/2014 due to a noticeable increase in the solvency index, efficiency index and total return index. The quick ratio increased from 2.99 to 6.23.
Celsus Therapeutics Plc (CLTX) was upgraded to D from D- on 6/2/2014 due to a noticeable increase in the solvency index, efficiency index and total return index. The quick ratio increased from 2.99 to 6.23.
NASDAQ
04/04/2025 12:41PM Eastern
Quotes delayed
